Page 2 - ஆல்பர்ட் மருத்துவ பள்ளி ஆஃப் பழுப்பு பல்கலைக்கழகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Experimental prostate cancer drug may improve COVID-19 survival
gulfnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gulfnews.com Daily Mail and Mail on Sunday newspapers.
Prostate Cancer Drug Improves COVID-19 Survival in Trial
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Experimental prostate cancer drug may improve COVID-19 survival; younger patients report long lasting symptoms
msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
Yves here. Aside from my general allergy to AI and algos (among other things, they are only as good as their training sets, which raises questions of accuracy and consistency of inputs), another reason to be concerned with health care algos is they require collection of patient data to work, which means yet another source of data vulnerability. Our reader IM Doc pointed out:
In the USA – we have multiple large tertiary referral centers that have quite the national reputation – I would include in that list MD Anderson, MAYO, Johns Hopkins, and …… The Scripps Clinic in La Jolla, California. I have innumerable patients that are seen there – they cater to that type of clientele. I first heard about this impending disaster over the weekend – and today things appeared to get immeasurably worse there…… see the following article……
E-Mail
(Boston) While a number of topical products designed to reduce the occurrence of sexually transmitted infections have been tested with largely disappointing results, researchers at Boston University School of Medicine (BUSM), Alpert Medical School of Brown University and Mapp Biopharmaceutical have now found that MB66, a vaginal film product containing monoclonal antibodies against human immunodeficiency virus-type 1 (HIV-1) and herpes simplex viruses types 1 and 2 (HSV-1 and 2), is safe and effective.
HIV-1 and HSV-1 and 2 are relatively common sexually transmitted infections associated with significant illness and sometimes even death. Though antiviral drugs can suppress viral concentrations and dramatically slow disease progression, these infections are incurable. Therefore, considerable effort is being directed toward prevention strategies.